![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Ruef Johannes Katus Hugo A
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.12, Iss.5, 2003-05, pp. : 781-797
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
New Targets for Antithrombotic Drugs
American Journal of Cardiovascular Drugs, Vol. 2, Iss. 4, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Hemker H.C. Giesen P.L. Wagenvoord R. Béguin S.
Expert Opinion on Emerging Drugs, Vol. 4, Iss. 1, 1999-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Pharmacogenetics of Antithrombotic Drugs
Current Pharmaceutical Design, Vol. 12, Iss. 19, 2006-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Multitarget Antithrombotic Drugs
Current Topics in Medicinal Chemistry, Vol. 11, Iss. 22, 2011-11 ,pp. :